Navigation Links
BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine

ioSante's lead products include Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel(R) (transdermal testosterone gel) in Phase III development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration. Additional information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this news release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "would," "likely," "expects," "anticipates," "estimates," "believes," "plans," "hopes," or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that could cause actual results to differ materially from those expressed in such forward-looking statements include the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving mar
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
3. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
4. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
5. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
6. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
(Date:7/30/2014)... 2014   Epic Sciences, Inc. ("Epic"), ... develops novel diagnostics to personalize and advance the ... completion of a $30 million Series C Preferred ... (RMI) and Arcus Ventures, existing investors Domain Associates, ... well as undisclosed individual investors. With the proceeds ...
Breaking Medicine Technology:Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
... Inc. (NYSE: HSP ), a leading global specialty ... will present at the Morgan Stanley Global Healthcare Conference on ... presentation is scheduled to begin at 8:35 a.m. Eastern time ... all interested parties through a live audiocast accessible via the ...
... Wright Therapy Products, Inc. announced today that ... Executive Officer of the company.  The company, based ... devices targeted for the treatment of lymphedema, venous ... Wright Therapy after holding senior financial and sales ...
Cached Medicine Technology:Industry Leaders Hinson and Friel Join Wright Therapy Products 2
(Date:7/30/2014)... Angeles, CA (PRWEB) July 30, 2014 ... the Chao Pinhole Surgical Technique®, the revolutionary minimally invasive ... Dennis Shanelec, considered by many of his peers to ... special guest speaker at a recent Chao Pinhole Surgical ... Alhambra, CA. Dr. Shanelec is the recipient of the ...
(Date:7/30/2014)... DC (PRWEB) July 30, 2014 ... appreciation to U.S. Sens. Thad Cochran (R-MS) and ... for improvements in telemedicine coverage under Medicare, Medicaid ... and Wicker, both Mississippi Republicans, introduced the Telehealth ... to a House version, H.R. 3306, introduced by ...
(Date:7/30/2014)... 2014 The Institute for Integrative Nutrition ... announce that Arianna Huffington has joined as a guest speaker ... Health Coach Training Program . , Arianna Huffington is the ... news and blogging site that won a Pulitzer Prize in ... books and was included on the Forbes “Most Powerful Women” ...
(Date:7/30/2014)... 2014 Frozen shoulder (Adhesive capsulitis) affects 10-20 ... develop this nasty condition which occurs most frequently in people ... up to two and half years if not treated. , ... with good reason: it can render your shoulder so stiff, ... if you aren't in too much pain to get dressed ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 (HealthDay ... the agitation that commonly strikes people with dementia, a new ... found evidence that watering plants, or sitting or strolling in ... The study authors cautioned that the effects of gardens on ... the evidence of a benefit is limited. But experts said ...
Breaking Medicine News(10 mins):Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3
... Denver, Colorado (June 1, 2011) Five advocacy organizations ... granted travel awards by the International Association for the ... the 14th World Conference on Lung Cancer, July 3-7 ... Australian Lung Foundation (Australia): The Australian Lung Foundation is ...
... (HealthDay News) -- Age alone should not be the sole determining ... a new study suggests. In following 216 women over the ... if screened properly, people who have facelifts after age 65 are ... , , More than 12 percent of the U.S. ...
... , WEDNESDAY, June 1 (HealthDay News) -- Boys ... significantly higher risk of developing a substance abuse problem ... "Our study, which is one of the largest ... supports the association between ADHD and substance abuse ...
... American Society for Gastrointestinal Endoscopy (ASGE) and the ... updated their 2003 joint guideline for reprocessing gastrointestinal ... account evolved technology and disinfection systems. ... in collaboration with multiple physician and nursing organizations, ...
... anticancer chemotherapeutics. However, it has some severe side effects ... the kidneys. Understanding the mechanisms underlying this toxicity could ... with cisplatin to protect the kidney during chemotherapy. In ... Dong, at Georgia Health Sciences University, Augusta, has now ...
... Dana-Farber Cancer Institute have identified an overactive network ... cells enriched in triple-negative breast tumors, a typically ... therapies. Kornelia Polyak, MD, PhD, a breast ... a large proportion of cells within these tumors ...
Cached Medicine News:Health News:5 advocacy organizations win travel awards to attend World Conference on Lung Cancer in Amsterdam 2Health News:5 advocacy organizations win travel awards to attend World Conference on Lung Cancer in Amsterdam 3Health News:Plastic Surgery Risks May Depend on More Than Age 2Health News:Children With ADHD More Prone to Substance Abuse: Study 2Health News:ASGE and SHEA issue updated multisociety guideline on reprocessing flexible gastrointestinal endoscopes 2Health News:ASGE and SHEA issue updated multisociety guideline on reprocessing flexible gastrointestinal endoscopes 3Health News:ASGE and SHEA issue updated multisociety guideline on reprocessing flexible gastrointestinal endoscopes 4Health News:Scientists identify overactive genes in aggressive breast cancers 2
... Oxylab pO2 probes feature response ... seconds for real-time monitoring of ... Oxylab LDFTM, measurements of pO2, ... be obtained from the same ...
Spherical Burr for FR030R, 5 mm....
Tungsten Carbide Burr "HM", 0,7 mm, ISO-No. 007....
"Rosen" burr, 0,7 mm, ISO-No. 007....
Medicine Products: